Treatment of leukemia by alloreactive lymphocytes and nonmyeloablative stem cell transplantation

Journal of Clinical Immunology

Volumn 22, Issue 2, 2002, Pages 64-69

  Slavin, Shimon ^a   Nagler, Arnon ^a   Shapira, Michael Y ^a   Aker, Mehmet ^b   Gabriel, Cividalli ^a   Or, Reuven ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b NONE

Author keywords

Bone marrow or blood stem cell transplantation; Donor lymphocyte infusion; Graft versus leukemia effect; Hematologic malignancies; Leukemia; Minitransplant; Nonmyeloablative stem cell transplantation

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE;

ADOPTIVE IMMUNOTHERAPY; ALLOIMMUNITY; BONE MARROW TRANSPLANTATION; CANCER CELL; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; GRAFT REJECTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC CELL; HOST CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; LEUKEMIA; MORTALITY; PRIORITY JOURNAL; RELAPSE; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 0036196406     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1014423617596     Document Type: Conference Paper

References (37)

1. Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation
2. Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation
3. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia
4. Graft-versus-leukemia reactions after bone marrow transplantation
5. Graft-versus-leukemia reactions in humans
6. Prevention of GVHD and induction of graft vs leukemia (GVL) effects: Will it ever be possible?
7. Cellular-mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man
8. Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes
9. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation
10. Effect of hematopoietic chimerism on the course of Rauscher's viral mouse leukemia
11. Time pattern of the antileukemia effect of graft-versus-host reaction in mice, I. Cellular events
12. Graft-versus-leukaemia reactivity induced by alloimmunization without augmentation of graft-versus-host reactivity
13. Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI)
14. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
15. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases
16. Engraftment and induction of GVL with fludarabine based non-ablative preparative regimens in patients with chronic lymphocytic leukemia and lymphoma
17. "Mini-allografts": Ongoing trials in humans
18. Outpatient PBSC allografts using immunosuppression with low-dose TBI before, and cyclosporine (CSP) and mycophenolate mofetil (MMF) after transplant
19. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse
20. Allogeneic cell mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic BMT for hematological malignancies
21. Allogeneic cell therapy of severe beta thalassemia major by displacement of host stem cells in mixed chimera by donor blood lymphocytes
22. Fludarabine based protocol for BMT in Fanconi anemia
23. A new non-myeloablative protocol using fludarabine and low-dose TBI in preparation for allogeneic blood stem cell transplantation for high risk patients with malignant and non-malignant disorders
24. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for a malignant lymphoma
25. Matched unrelated bone marrow transplantation (BMT) using a non-myeloablative conditioning regimen
26. Secondary allogeneic stem cell transplantation (alloSCT) using a non-myeloablative conditioning regimen for patients with hematological malignancies
27. Treatment of myeloid leukemias with non-myeloablative stem cell transplantation: Accomplishments and future goals
28. Long-term survival of skin allografts in mice treated with fractionated total lymphoid irradiation
29. Total lymphoid irradiation
30. Transplantation of allogeneic bone marrow without graft vs host disease using total lymphoid irradiation
31. Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI)
32. Anti-tumor effects of allogeneic bone marrow transplantation in (NZB x NZW)F1 hybrids with spontaneous lymphosarcoma
33. Allogeneic cell therapy for a murine mammary carcinoma
34. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
35. Cancer immunotherapy with alloreactive lymphocytes
36. Apperley J for the chronic leukemia Working Party of the EBMT
37. Immunotherapy of cancer with alloreactive lymphocytes